With over three decades in the Medtech sector, Erica has experience leading and developing a wide range of medical devices, diagnostics, and pharmaceutical advancements across many conditions and disease sectors. She had the privilege of steering Silk Road Medical, as the CEO, for eleven years. She successfully navigated the company from early venture funding to a triumphant IPO in 2019, overseeing its expansion from a 25-person startup to a flourishing 500-employee organization. Following its successful IPO, Silk Road Medical was acquired by Boston Scientific in 2024.

Among her most valuable experiences was her role as Chief Operating Officer (COO) of Medicines360 from 2010 to 2012. She helped to secure the first US commercial partnership that furthered the organization’s mission of serving all women, regardless of means, in the United States. Erica remained on the Board of Medicines360 from 2012 to 2014. She is proud to have re-joined Medicines360 in 2024 as a board member, to help guide the organization through a new era of serving women across the globe.

Erica also served as an advisor to the CEO and Board of Alydia Health, a women’s health company, and helped to shepherd an important, lifesaving post-partum hemorrhage device to market.

Today, Erica spends her professional time serving as a director and chairing the Compensation Committees of Lightforce Orthodontics and Sight Sciences (NASDAQ: SGHT). She is a director at Histosonics Inc., and Axena Health Inc. She is passionate about science and technologies addressing health span and lifespan and enjoys advancing her knowledge of best practices for longevity. She has been humbled to receive recognitions such as 2023 MedTech MVP, Forbes “50 over 50” Women, Silicon Valley’s “Power 100” top CEOs, and EY Entrepreneur of the Year, and is a named inventor on more than 25 US patents in medical technologies.